Matthew Dallas
2018
In 2018, Matthew Dallas earned a total compensation of $1.3M as Chief Financial Officer at AVEO Pharmaceuticals, a 29% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $97,152 |
|---|---|
| Option Awards | $879,330 |
| Salary | $352,000 |
| Other | $7,278 |
| Total | $1,335,760 |
Dallas received $879.3K in option awards, accounting for 66% of the total pay in 2018.
Dallas also received $97.2K in non-equity incentive plan, $352K in salary and $7.3K in other compensation.
Rankings
In 2018, Matthew Dallas' compensation ranked 7,742nd out of 14,244 executives tracked by ExecPay. In other words, Dallas earned more than 45.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,742 out of 14,244 | 46th |
Division Manufacturing | 3,019 out of 5,765 | 48th |
Major group Chemicals And Allied Products | 1,130 out of 2,128 | 47th |
Industry group Drugs | 953 out of 1,817 | 48th |
Industry Pharmaceutical Preparations | 743 out of 1,391 | 47th |
Pay ratio
| Matthew Dallas' Pay | $1,335,760 |
|---|---|
| Median Employee's Pay | $248,144 |
| Pay Ratio | 5to 1 |
In 2018, the annual total compensation of Matthew Dallas was $1,335,760.
The annual total compensation of the median employee at AVEO Pharmaceuticals was $248,144.
The ratio of Matthew Dallas' pay to the pay of median employee was therefore 5 to one.
Source: SEC filing on April 30, 2019.
Dallas' colleagues
We found four more compensation records of executives who worked with Matthew Dallas at AVEO Pharmaceuticals in 2018.